Since sFRP4 is a known antagonist of the Wnt signalling pathway, its reduced expression in tumours suggests that loss of sFRP4 may contribute to Wnt pathway activation, which is linked to cancer progression. This evidence concerns the gene SFRP4 and neoplasm.